Abemaciclib Combo Seen to Slow Progression in Phase 3 Advanced Breast Cancer Trial

Abemaciclib Combo Seen to Slow Progression in Phase 3 Advanced Breast Cancer Trial
An interim analysis from the Phase 3 trial known as MONARCH 3 showed that adding abemaciclib to an aromatase inhibitor — Femara (letrozole) or Arimidex (anastrozole) — helped to treat certain postmenopausal women with advanced breast cancer, lengthening their time to disease progression. The trial studied the combination, versus an aromatase inhibitor alone, in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. With these findings MONARCH 3 met its primary endpoint, in addition to a secondary endpoint, that of objective response rate (ORR). "Today marks another important milestone in our clinical development program for abemaciclib, a drug we believe has the potential to be best in class," Levi Garraway, senior vice president, global development and medical affairs, Lilly Oncology, said in a news release. "We are very excited about the results seen in patients with breast cancer … Along with additional abemaciclib clinical trials in other tumor types, these data underscore Lilly's commitment to delivering life-changing medicines to treat and cure people living with cancer around the world." When cell's divide, several "checkpoint" proteins control the division process. When these proteins are faulty, uncontrolled cell growth may result, leading to cancer formation. In many cancers, increased signaling from the checkpoint proteins CDK4 and CDK6 has been shown to heighten cell proliferation in an uncontrolled manner, which blocking (or inhibiting) these proteins could prevent. Abemaciclib is a CDK4/6 oral inhibitor. In HR-positive breast cancer cell lines, abemaciclib was able to halt cell prolif
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.